Randomized controlled trials of new oral anticoagulants for stroke prevention in atrial fibrillation

Current Opinion in Cardiology

Volumn 27, Issue 4, 2012, Pages 331-339

  Liew, Aaron ^a   Eikelboom, John W ^a   O'Donnell, Martin ^b  

^a MCMASTER UNIVERSITY   (Canada)

^b UNIVERSITY HOSPITAL GALWAY   (Ireland)

Author keywords

atrial fibrillation; oral anticoagulants; stroke; systemic embolism

Indexed keywords

ACENOCOUMAROL; ACETYLSALICYLIC ACID; ANTIVITAMIN K; APIXABAN; CLOPIDOGREL; DABIGATRAN; EDOXABAN; ESTERASE; FLUINDIONE; IRBESARTAN; LOW MOLECULAR WEIGHT HEPARIN; PHENPROCOUMON; PLACEBO; RIVAROXABAN; WARFARIN; XIMELAGATRAN;

BLEEDING; BRAIN HEMORRHAGE; CARDIAC PATIENT; CONFIDENCE INTERVAL; CREATININE CLEARANCE; DRUG EFFICACY; DRUG HALF LIFE; DRUG SAFETY; DRUG WITHDRAWAL; DYSPEPSIA; FOOD DRUG INTERACTION; GASTROINTESTINAL HEMORRHAGE; HEART ATRIUM FIBRILLATION; HOSPITALIZATION; HUMAN; LIVER TOXICITY; MEDICAL SOCIETY; MORTALITY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; STROKE;

ANTICOAGULANTS; ATRIAL FIBRILLATION; HUMANS; PLATELET AGGREGATION INHIBITORS; PREVALENCE; RANDOMIZED CONTROLLED TRIALS AS TOPIC; STROKE; UNITED STATES; VITAMIN K; WARFARIN;

EID: 84862300138     PISSN: 02684705     EISSN: 15317080     Source Type: Journal    
DOI: 10.1097/HCO.0b013e3283540857     Document Type: Review

References (39)

1. Roger VL, Go AS, Lloyd-Jones DM, et al. Heart disease and stroke statistics -2012 update: A report from the American Heart Association. Circulation 2012; 125:e2-e220.
2. Naccarelli GV, Varker H, Lin J, Schulman KL. Increasing prevalence of atrial fibrillation and flutter in the United States. Am J Cardiol 2009; 104:1534-1539.
3. Hart RG, Pearce LA, Aguilar MI. Meta-Analysis: Antithrombotic therapy to prevent stroke in patients who have nonvalvular atrial fibrillation. Ann Intern Med 2007; 146:857-867.
4. Lip GY, Andreotti F, Fauchier L, et al. Bleeding risk assessment and management in atrial fibrillation patients. Executive Summary of a Position Document from the European Heart Rhythm Association [EHRA], endorsed by the European Society of Cardiology [ESC] Working Group on Thrombosis. Thromb Haemost 2011; 106:997-1011.
5. Budnitz DS, Lovegrove MC, Shehab N, Richards CL. Emergency hospitalizations for adverse drug events in older Americans. N Engl J Med 2011; 365:2002-2012.
6. Connolly SJ, Pogue J, Hart RG, et al. Effect of clopidogrel added to aspirin in patients with atrial fibrillation. N Engl J Med 2009; 360:2066-2078.
7. Connolly S, Pogue J, Hart R, et al. Clopidogrel plus aspirin versus oral anticoagulation for atrial fibrillation in the Atrial fibrillation Clopidogrel Trial with Irbesartan for prevention of Vascular Events (ACTIVE W): A randomised controlled trial. Lancet 2006; 367:1903-1912.
8. Cairns JA, Connolly S, McMurtry S, et al. Canadian Cardiovascular Society atrial fibrillation guidelines 2010: Prevention of stroke and systemic thromboembolism in atrial fibrillation and flutter. Can J Cardiol 2011; 27:74-90.
9. Camm AJ, Kirchhof P, Lip GY, et al. Guidelines for the management of atrial fibrillation: The Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology (ESC). Eur Heart J 2010; 31:2369-2429.
10. Wann LS, Curtis AB, Ellenbogen KA, et al. 2011 ACCF/AHA/HRS focused update on the management of patients with atrial fibrillation (update on dabigatran): A report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines. J Am Coll Cardiol 2011; 57:1330-1337.
11. Fuster V, Ryden LE, Cannom DS, et al. 2011 ACCF/AHA/HRS focused updates incorporated into the ACC/AHA/ESC 2006 Guidelines for the management of patients with atrial fibrillation: A report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines developed in partnership with the European Society of Cardiology and in collaboration with the European Heart Rhythm Association and the Heart Rhythm Society. J Am Coll Cardiol 2011; 57:e101-e198.
12. Go AS, Hylek EM, Borowsky LH, et al. Warfarin use among ambulatory patients with nonvalvular atrial fibrillation: The anticoagulation and risk factors in atrial fibrillation (ATRIA) study. Ann Intern Med 1999; 131:927-934.
13. Deplanque D, Leys D, Parnetti L, et al. Stroke prevention and atrial fibrillation: Reasons leading to an inappropriate management. Main results of the SAFE II study. Br J Clin Pharmacol 2004; 57:798-806.
14. Lin LJ, Cheng MH, Lee CH, et al. Compliance with antithrombotic prescribing guidelines for patients with atrial fibrillation - A nationwide descriptive study in Taiwan. Clin Ther 2008; 30:1726-1736.
15. Connolly SJ, Pogue J, Eikelboom J, et al. Benefit of oral anticoagulant over antiplatelet therapy in atrial fibrillation depends on the quality of international normalized ratio control achieved by centers and countries as measured by time in therapeutic range. Circulation 2008; 118:2029-2037.
16. Nieuwlaat R, Connolly BJ, Hubers LM, et al. Quality of individual INR control and the risk of stroke and bleeding events in atrial fibrillation patients: A nested case control analysis of the ACTIVEWstudy. Thromb Res 2011. [Epub ahead of print]
17. Gallagher AM, Setakis E, Plumb JM, et al. Risks of stroke and mortality associated with suboptimal anticoagulation in atrial fibrillation patients. Thromb Haemost 2011; 106:968-977.
18. Rose AJ, Hylek EM, Ozonoff A, et al. Risk-Adjusted percentage time in therapeutic range as a quality indicator for outpatient oral anticoagulation: Results of the Veterans Affairs Study to Improve Anticoagulation (VARIA). Circ Cardiovasc Qual Outcomes 2011; 4:22-29.
19. Baker WL, Cios DA, Sander SD, Coleman CI. Meta-Analysis to assess the quality of warfarin control in atrial fibrillation patients in the United States. J Manag Care Pharm 2009; 15:244-252.
20. Ford GA, Choy AM, Deedwania P, et al. Direct thrombin inhibition and stroke prevention in elderly patients with atrial fibrillation: Axperience from the SPORTIF III and V Trials. Stroke 2007; 38:2965-2971.
21. Pisters R, Lane DA, Nieuwlaat R, et al. A novel user-friendly score (HASBLED) to assess 1-year risk of major bleeding in patients with atrial fibrillation: The Euro Heart Survey. Chest 2010; 138:1093-1100.
22. Connolly SJ, Ezekowitz MD, Yusuf S, et al. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med 2009; 361:1139-1151.
23. Connolly SJ, Ezekowitz MD, Yusuf S, et al. Newly identified events in the RE-LY trial. N Engl J Med 2010; 363:1875-1876.
24. Hohnloser SH, Oldgren J, Yang S, et al. Myocardial ischemic events in patients with atrial fibrillation treated with dabigatran or warfarin in the RE-LY Trial. Circulation 2012; 125:669-676.
25. LipGY, Lane DA. Does warfarin for stroke thromboprophylaxis protect against MI in atrial fibrillation patients? Am J Med 2010; 123:785-789.
26. Uchino K, Hernandez AV. Dabigatran association with higher risk of acute coronary events: Meta-Analysis of noninferiority randomized controlled trials. Arch Intern Med 2012; 172:397-402.
27. Ezekowitz MD, Wallentin L, Connolly SJ, et al. Dabigatran and warfarin in vitamin K antagonist-naive and -experienced cohorts with atrial fibrillation. Circulation 2010; 122:2246-2253.
28. Diener HC, Connolly SJ, Ezekowitz MD, et al. Dabigatran compared with warfarin in patients with atrial fibrillation and previous transient ischaemic attack or stroke: A subgroup analysis of the RE-LY trial. Lancet Neurol 2010; 9:1157-1163.
29. Hori M, Connolly SJ, Ezekowitz MD, et al. Efficacy and safety of dabigatran vs. warfarin in patients with atrial fibrillation - sub-Analysis in Japanese population in RE-LY trial. Circ J 2011; 75:800-805.
30. Nagarakanti R, Ezekowitz MD, Oldgren J, et al. Dabigatran versus warfarin in patients with atrial fibrillation: An analysis of patients undergoing cardioversion. Circulation 2011; 123:131-136.
31. Wallentin L, Yusuf S, Ezekowitz MD, et al. Efficacy and safety of dabigatran compared with warfarin at different levels of international normalised ratio control for stroke prevention in atrial fibrillation: An analysis of the RE-LY trial. Lancet 2010; 376:975-983.
32. Eikelboom JW, Wallentin L, Connolly SJ, et al. Risk of bleeding with 2 doses of dabigatran compared with warfarin in older and younger patients with atrial fibrillation: An analysis of the randomized evaluation of long-term anticoagulant therapy (RE-LY) trial. Circulation 2012; 123:2363-2372.
33. Connolly SJ, Eikelboom J, Joyner C, et al. Apixaban in patients with atrial fibrillation. N Engl J Med 2011; 364:806-817.
34. Eikelboom JW, O'Donnell M, Yusuf S, et al. Rationale and design of AVERROES: Apixaban versus acetylsalicylic acid to prevent stroke in atrial fibrillation patients who have failed or are unsuitable for vitamin K antagonist treatment. Am Heart J 2010; 159:348-353; e341.
35. Lopes RD, Alexander JH, Al-Khatib SM, et al. Apixaban for reduction in stroke and other ThromboemboLic events in atrial fibrillation (ARISTOTLE) trial: Design and rationale. Am Heart J 2010; 159:331-339.
36. Granger CB, Alexander JH, McMurray JJ, et al. Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med 2011; 365:981-992.
37. Patel MR, Mahaffey KW, Garg J, et al. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med 2011; 365:883-891.
38. Fox KA, Piccini JP, Wojdyla D, et al. Prevention of stroke and systemic embolism with rivaroxaban compared with warfarin in patients with nonvalvular atrial fibrillation and moderate renal impairment. Eur Heart J 2011; 32:2387-2394.
39. Ruff CT, Giugliano RP, Antman EM, et al. Evaluation of the novel factor Xa inhibitor edoxaban compared with warfarin in patients with atrial fibrillation: Design and rationale for the Effective aNticoaGulation with factor xA next GEneration in Atrial Fibrillation-Thrombolysis In Myocardial Infarction study 48 (ENGAGE AF-TIMI 48). Am Heart J 2010; 160:635-641.